Backed by Nvidia and Pfizer, Israeli AI medical startup raises USD80m
Israeli startup CytoReason has announced it has secured USD 80 million in a private funding round, with notable backing from U.S. semiconductor company Nvidia and pharmaceutical leader Pfizer. Additional participation came from U.S. medical equipment manufacturer Thermo Fisher and the Jerusalem-based venture capital platform OurCrowd.
The Tel Aviv-based company plans to utilise the newly raised capital to broaden the application of its disease models across additional indications and enhance its proprietary molecular and clinical data. CytoReason also intends to establish a U.S. hub in Cambridge, Massachusetts, later this year, and expand its workforce. Currently, the company employs over 120 people, primarily based in Israel.
Founded in 2016, CytoReason leverages artificial intelligence to create computational disease models aimed at enhancing drug discovery.
Fischer (FBC & Co.) advised Nvidia in the fundraising, with its team comprising Raz Tepper, M&A partner and co-head of the firm’s Hi-Tech, Technology and Venture Capital practice, together with Hi-Tech partner Shmulik Fried, and associates Zorick Shifman and Dima Kassim.
